Pfizer Announces Presentation of Data from a Phase 2 Study of its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older
The U.S. FDA awarded Breakthrough Therapy Designation for this potential indication based on these Phase 2 data – – –…